INTRODUCTION
We have recently demonstrated the presence of three distinct immunoreactive species of parathyroid hormone (PTH) ' in human serum (1) . These species differ in mol wt, immunological characteristics, and kinetic properties. One has an estimated mol wt of 9,500, similar to that for glandular PTH, the second, 7,000-7,500 mol wt and the third, 4,500-5,000 mol wt. imimunoreactive fragments of circulating PTH has been demonstrated in two other laboratories (2, 3) , but there is disagreement whether these circulating fragments have biological activity (4, 5) .
Chase and Aurbach (6) demonstrated that PTH activates adenylate cyclase in renal cortex and increases the urinary excretion of adenosine 3',5'-monophosphate (cyclic AMP) (7). They postulated that the activation of adenylate cyclase with its resultant increase in intracellular cyclic AMP mediates the effects of PTH on the kidneys
In order to assess the biological activity of circulating PTH fragments, we determined their ability to activate renal cortical adenylate cyclase.
METHODS
Preparation and assay of renal cortical adenylate cyclase. The diluent for all PTH fractions and for bovine PTH was 0.01 N acetic acid. The total volume of the incubation
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The Journal of Clinical Investigation Volume 52 February 1973 mixture was 0.065 ml. The accumulation of 32P-cyclic 3',5'-AMP was determined as previously described (10) . Boiled enzyme controls contained 10 pmol of 8P-cyclic 3',5'-AMP, which was subtracted from the values shown in the results.
Preparation of parathyroid fragments from human serum.
PTH fractions were derived from the sera of 23 patients with primary hyperparathyroidism. In each of five experiments, the sera from three to five patients were pooled (2-5 ml per patient), concentrated by Amicon filtration (Amicon Corp., Lexington, Mass.), and fractionated on Bio gel P-10 (Bio-Rad Laboratories, Richmond, Calif.), as previously described (1) . Eluted fractions were assayed by radioimmunoassay using a single antiserum, CH-824 (11). 3'I-bovine PTH served as a marker for glandular PTH. Three distinct immunoassayable peaks emerged with each filtration in a highly reproducible pattern with estimated mol wt of 9,500, 7,000-7,500, and 4,500-5,000. Narrow cuts from the top of each peak were made for pooling of individual immunoreactive peaks. The pooled peaks were concentrated 10-fold by partial lyophilization and again 10-fold by use of VirTis Bio-dryer (VirTis Co., Inc., Gardiner, N. Y.). The latter procedure was required to remove most of the ammonium acetate, the eluent buffer. The final volume of all concentrated PTH fractions was 0.2 ml.
For control fractions, the sera from 11 hypoparathyroid patients were pooled, concentrated, and fractionated in a manner identical to that used for hyperparathyroid sera. Immunoassayable PTH could not be detected in any of these samples. Pools were made of the fractions where the three immunoassayable peaks would be expected to elute in the gel chromatography procedure using hyperparathyroid serum.
Blocking experiments were performed by preincubating 0.1 ml of the synthetic N-terminal peptide (1-34 amino acids) of bovine PTH 2 (750 /Ag/ml) with 0.1 ml of the antiserum CH-824 (1:50,000) for 3 days before immunoassay of the hyperparathyroid peaks.
RESULTS
Effects of PTH fragments on activation of adenylate cyclase. The effects of the three immunoreactive peaks on the activation of adenylate cyclase in a particulate preparation of rat renal cortex is shown in Table I . Peaks I and III produced four-to sixfold increases above control values. In contrast, peak II did not activate adenylate cyclase. Concentration-response curves for peaks I and III and for purified bovine PTH are shown in Fig. 1 . The responses are parallel. It would appear from these curves that 25 IAI of peaks I and III from hyperparathyroid sera contained approximately the equivalent of 5 Ag/ml of bovine PTH.
Effects of bovine PTH antibody on the activation of adenylate cyclase by peaks I and III. The effect of antiserum to bovine PTH on the accumulation of cyclic AMP produced by peaks I and III and by purified bovine PTH was examined (Table II) Immunological competition between human fragments and synthetic bovine fragment. As shown in Table  III , preincubation of the biologically active N-terminal synthetic bovine peptide fragment, 1-34, with antibovine PTH sera resulted in significant decrease of antibodybinding capacity for peaks I and III. However, blocking of antibody combining sites by the synthetic peptide did not result in any loss of immunoreactivity for peak II.
DISCUSSION
Information concerning the biological activity of circulating PTH fragments has basic physiologic importance and practical implications for the interpretation of immunoassay results. If most of circulating PTH is biologically inactive (4) , tissues are exposed to active hormone only after bursts of secretion by the parathyroid glands. This exposure would be brief since the half-life of glandular PTH approximates 20 min (12) . On the other hand, if one or more PTH fragments possess biologic activity, tissues would be exposed to effective hormone for long periods after a particular stimulus to PTH secretion. This is evident from the observation that PTH fragments have half-lives of the order of hours rather than minutes. In this scheme, the fragments would subserve the function of long-term stabilization of PTH effects (5) .
Interpretation of immunoassays of PTH depends to a large extent on the biological activity of the fragments. If one or more immunoreactive fragment is biologically active, an assay would reflect exposure of end organs to specific stimulation. If the fragments are inert, immunoassays would provide only indirect information about parathyroid secretion.
The demonstration that peak III is active in renal tissue indicates that at least one target organ is subjected to prolonged exposure to active hormone. Whether this fragment is also active in other tissues remains to be explored. The presence of long-persisting, biologically, and immunologically active PTH fragment in the circulation explains why, according to reports from several laboratories, plasma or serum PTH may be normal in some patients with primary hyperparathyroidism (13, 14) . Antisera having high affinity for glandular hormone but low affinity for peak III would be expected to yield assay results in the normal range in hyperparathyroidism even though the actual concentration of biologically active hormone is high.
The composition of peak III is unknown. Blocking experiments suggest that it contains antigenic determinants located in the N-terminal 1-34 amino acid residues of bovine PTH. The possibility that peak III is contaminated with substance capable of activating adenylate cyclase cannot be absolutely excluded but appears to be highly unlikely. The hypoparathyroid control fractionations provide strong evidence against nonparathyroid contaminants of peak III.
The observation that PTH antibodies do not block biological activity indicates that the biologically and immunologically active sites are distinct.
The difference between our results and those of others can be explained by differences in procedure of serum fractionation and methods of testing biological activity. Our active peak III constitutes approximately 25% of immunoreactivity in hyperparathyroid serum. It has not been described by others, presumably because use of concentrated samples in our system makes possible a better separation of fragments; in unconcentrated samples, separation of the 7,000-7,500 mol wt from the 4,500-5,000 mol wt peak may not be possible. Concentrating samples has the added advantage of yielding sufficient material for direct assay in the renal adenylate cyclase system. It has the drawback of possible artefactual generation of PTH fragments, but this possibility appears to be excluded by appropriate control experiments (1).
